As IL-6 involvement is observed in the early stages of the disease, where the myeloma interacts with the stroma and plays a key role in cancer cell survival, anti-IL-6 therapy in the early stages of the disease may have more promising results [25]. This evidence concerns the gene IL6 and plasma cell myeloma.